NASDAQ
Apimeds Pharmaceuticals US, Inc (APUS) has a free cash flow growth of 43.95% as of Friday, May 29, 2026. This represents a 101.07% increase compared to its 12-month average of -4126.02%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.